TETRALOGIC PHARMACEUTICALS CORP (TLOG) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 95 transactions totaling $27.4M, demonstrating a bullish sentiment with $26.5M in net insider flow. The most recent transaction on Feb 9, 2016 involved a sale of 230,507 shares valued at $36.9K.
No significant insider buying has been recorded for TLOG in the recent period.
No significant insider selling has been recorded for TLOG in the recent period.
Based on recent SEC filings, insider sentiment for TLOG is bullish with an Insider Alignment Score of 98/100 and a net flow of $26.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at TETRALOGIC PHARMACEUTICALS CORP (TLOG) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading TLOG stock, having executed 95 transactions in the past 90 days. The most active insider is Robert Liptak (Executive), who has made 7 transactions totaling $16.2M.
Get notified when executives and directors at TLOG file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 9, 2016 | II Gp, L.p. Clarus Ventures | Executive | Sale | 230,507 | $0.16 | $36.9K | |
| Feb 8, 2016 | II Gp, L.p. Clarus Ventures | Executive | Sale | 103,123 | $0.19 | $19.6K | |
| Feb 5, 2016 | Ii, Llc Clarus Ventures | Executive | Sale | 832,881 | $0.20 | $166.6K | |
| Feb 4, 2016 | Ii, Llc Clarus Ventures | Executive | Sale | 500,026 | $0.14 | $70.0K | |
| Feb 3, 2016 | Ii, Llc Clarus Ventures | Executive | Sale | 82,583 | $0.15 | $12.4K | |
| Feb 2, 2016 | Simon Nicholas | Executive | Sale | 176,306 | $0.17 | $30.0K | |
| Feb 1, 2016 | Simon Nicholas | Executive | Sale | 140,000 | $0.20 | $28.0K | |
| Jan 29, 2016 | Simon Nicholas | Executive | Sale | 52,826 | $0.26 | $13.7K | |
| Jan 28, 2016 | Liptak Robert | Executive | Sale | 32,521 | $0.26 | $8.5K | |
| Jan 27, 2016 | Liptak Robert | Executive | Sale | 209,984 | $0.27 | $56.7K | |
| Jan 26, 2016 | Liptak Robert | Executive | Sale | 69,425 | $0.30 | $20.8K | |
| Jul 10, 2015 | L. Pecora Andrew | Executive | Purchase | 2,100 | $2.69 | $5.6K | |
| Jul 10, 2015 | L. Pecora Andrew | Executive | Purchase | 10,000 | $2.44 | $24.4K | |
| Jul 10, 2015 | L. Pecora Andrew | Executive | Purchase | 9,200 | $2.79 | $25.7K | |
| Jul 10, 2015 | L. Pecora Andrew | Executive | Purchase | 800 | $2.75 | $2.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 49 | $26.9M | 67.3% |
Conversion(C) | 27 | $12.4M | 30.9% |
Sale(S) | 11 | $463.1K | 1.2% |
Exercise (Options)(X) | 8 | $259.5K | 0.6% |
Insiders at TETRALOGIC PHARMACEUTICALS CORP are accumulating shares at an accelerated pace. With 16 insiders making 95 transactions totaling $26.9M in purchases versus $463.1K in sales, the net buying activity of $26.5M signals strong executive confidence. Robert Liptak (Executive) leads the buying activity with $16.2M in transactions across all time.